Trident Texofab Ltd.

As of June 30, 2026, Trident Texofab Ltd. carries a market capitalization of 535.80M, placing it among publicly traded companies globally. Its enterprise value stands at 535.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Trident Texofab Ltd. has 15.00M shares outstanding.

As of June 30, 2026, Trident Texofab Ltd. trades at a trailing price-to-earnings ratio of 253.39.

As of June 30, 2026, Trident Texofab Ltd. trades at an EV/EBITDA multiple of 16.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.46 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 30.35 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 535.80M versus a market cap of 535.80M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 20.02M in revenue per employee across its workforce of 58.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Trident Texofab Ltd. recorded 3.90M in income tax expense. That works out to an effective tax rate of 64.98, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.00M, leaving 2.10M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Trident Texofab Ltd.'s stock has declined approximately 95.24% over the past 52 weeks. The 50-day moving average sits at 21.77, while the 200-day moving average is 68.79.

Over the twelve months ended June 30, 2026, Trident Texofab Ltd. generated 1.16B in revenue and converted that into 2.10M in net income, yielding earnings per share of 0.14. EBITDA reached 33.44M, while operating income came in at 28.93M.

Over the twelve months ended June 30, 2026, Trident Texofab Ltd. posted a gross margin of 9.46, reflecting its pricing power and cost economics. The operating margin of 2.49 and net profit margin of 0.18 provide insight into operational efficiency.

Trident Texofab Ltd.'s most recent stock split took place on August 11, 2020 with a 5:12 split ratio.